Sutro Biopharma (STRO) Long-Term Debt Repayments (2019 - 2024)

Sutro Biopharma has disclosed Long-Term Debt Repayments across 5 years of filings, most recently posting $4.1 million for Q1 2024.

• Long-Term Debt Repayments for Q1 2024 came in at $4.1 million, up 30.66% year-over-year; the trailing twelve-month figure through Dec 2024 was $4.1 million (down 67.34% YoY), and the FY2024 annual result was $4.1 million, down 67.34% from the prior year.
• Long-Term Debt Repayments came in at $4.1 million for Q1 2024 at Sutro Biopharma, up from $3.1 million in the prior quarter.
• In the past five years, Long-Term Debt Repayments ranged from a high of $10.0 million in Q1 2020 to a low of $3.1 million in Q3 2022.
• The 4-year median for Long-Term Debt Repayments is $3.1 million (2022), against an average of $4.1 million.
• Across the five-year window, Long-Term Debt Repayments jumped 1900.0% in 2020 and changed 0.0% in 2023, its largest moves.
• Sutro Biopharma's Long-Term Debt Repayments stood at $10.0 million in 2020, then tumbled by 68.75% to $3.1 million in 2022, then changed by 0.0% to $3.1 million in 2023, then soared by 30.66% to $4.1 million in 2024.
• The last three Long-Term Debt Repayments figures came in at $4.1 million (Q1 2024), $3.1 million (Q4 2023), and $3.1 million (Q3 2023), per Business Quant data.